The global core biopsy needles market was valued at USD 950 million in 2025. The market is projected to grow from USD 1015 million in 2026 to USD 1718 million by 2034, exhibiting a compound annual growth rate of 6.8% during the forecast period. Contrive Datum Insights presents this information in its report titled "Core Biopsy Needles Market Size, Share & Industry Analysis, By Type (Full-automated core needle biopsy device, Semi-automated core needle biopsy device, Manual core needle biopsy device), Application (Hospitals, Clinics, Others), Clinical indication (Breast Biopsy, Prostate Biopsy, Kidney and Liver Biopsy, Lung Biopsy, Others), Imaging guidance (Ultrasound-guided, Stereotactic/Mammography-guided, CT-guided, MRI-guided), Distribution channel (Direct/Institutional Sales, Distributor Sales), and Regional Forecast, 2026-2034".
Core needle biopsy devices are handheld or gun-style instruments that extract a solid cylindrical tissue sample from a suspicious lesion for histopathological diagnosis, most commonly used to confirm or rule out breast, prostate and other solid-organ cancers. The category spans manual, semi-automated (spring-loaded) and full-automated designs used under ultrasound, stereotactic, MRI or CT imaging guidance. Buyers are hospital radiology and pathology departments, diagnostic imaging centers and outpatient clinics that perform image-guided tissue sampling.
Rising global cancer screening and early-detection program expansion
Rising global cancer screening and early-detection program expansion is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 6.8% a year, the type lines exposed to it move fastest: Full-automated core needle biopsy device compounds at 9.33%, taking its share of revenue from 42% to 52% and its value from USD 399 million to USD 893.4 million.
Where the forecast could be beaten: screening-program funding expansion and faster automated-device conversion pull adoption ahead of the base case in every region. The study puts that case at USD 1795.3 million in 2034, against USD 1718 million in the base.
The downside is specific. Reimbursement tightening and slower hospital capital equipment cycles delay automated-device conversion and compress average selling prices relative to the base case, and 2034 revenue lands at USD 1625.2 million. Semi-automated core needle biopsy device is the drag, 50% of the 2025 base compounding at 4.73% while the market runs at 6.8%.
Semi-automated core needle biopsy device Scale Against Full-automated core needle biopsy device Momentum
Competition in the global core biopsy needles market runs along the type axis, not the regional one. Semi-automated core needle biopsy device holds 50% of 2025 revenue at USD 475 million and remains the largest line through 2034 at 42%, making it the position hardest for a challenger to take. Full-automated core needle biopsy device, growing at 9.33%, is where share actually changes hands. A supplier established in one is not thereby established in the other, so a field of this size persists in a market of USD 950 million.
Additional Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Application | Hospitals | 60% · USD 570 million | Clinics 7.87% |
| Clinical indication | Breast Biopsy | 42% · USD 399 million | Lung Biopsy 8.65% |
| Imaging guidance | Ultrasound-guided | 55% · USD 522.5 million | MRI-guided 10.65% |
| Distribution channel | Direct/Institutional Sales | 64% · USD 608 million | — |
- North America was the largest region in 2025, holding 38% of global revenue at USD 361 million and reaching USD 601.3 million by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 26% in 2025 to 30% in 2034, with revenue growing from USD 247 million to USD 515.4 million.
- Middle East and Africa remains the smallest region throughout, at 4% of 2025 revenue and 4.5% by 2034.
- Semi-automated core needle biopsy device was the leading type line in 2025, taking 50% of revenue at USD 475 million.
- No type line grows faster than Full-automated core needle biopsy device, at a projected 9.33%.
- The United States is the largest single country market at USD 306.9 million in 2025, 32.3% of global revenue.
Every year from 2020 to 2034 is reported, with revenue and growth for each line across five axes: by type, and by application, clinical indication, imaging guidance and distribution channel. The headline total carries bear, base and bull cases at USD 1625.2 million and USD 1795.3 million by 2034. The study also breaks out all five regions to country level, sets out the competitive landscape, and documents the method behind every estimate. Available as a PDF, with a free sample on request.